Synergistic activation of human pregnane X receptor by binary cocktails of pharmaceutical and environmental compounds

Vanessa Delfosse¹,²,³, *, Béatrice Dendele³,⁴,⁵,⁶, *, Tiphaine Huet¹,²,³, *, Marina Grimaldi³,⁴,⁵,⁶, Abdelhay Boulahhtouf³,⁴,⁵,⁶, Sabine Gerbal-Chaloin³,⁷, Bertrand Beucher³,⁸,⁹, Dominique Roecklin¹⁰, Christina Muller¹⁰, Roger Rahmani¹¹, Vincent Cavallès³,⁴,⁵,⁶, Martine Daujat-Chavanieu³,⁷,¹², Valérie Vivat¹⁰, Jean-Marc Pascussi³,⁸,⁹, Patrick Balaguer³,⁴,⁵,⁶, ** & William Bourguet¹,²,³, **

Humans are chronically exposed to multiple exogenous substances, including environmental pollutants, drugs and dietary components. Many of these compounds are suspected to impact human health, and their combination in complex mixtures could exacerbate their harmful effects. Here we demonstrate that a pharmaceutical oestrogen and a persistent organochlorine pesticide, both exhibiting low efficacy when studied separately, cooperatively bind to the pregnane X receptor, leading to synergistic activation. Biophysical analysis shows that each ligand enhances the binding affinity of the other, so the binary mixture induces a substantial biological response at doses at which each chemical individually is inactive. High-resolution crystal structures reveal the structural basis for the observed cooperativity. Our results suggest that the formation of ‘supramolecular ligands’ within the ligand-binding pocket of nuclear receptors contributes to the synergistic toxic effect of chemical mixtures, which may have broad implications for the fields of endocrine disruption, toxicology and chemical risk assessment.

¹Inserm U1054, Montpellier 34090, France. ²CNRS UMR5048, Centre de Biochimie Structurale, Montpellier 34090, France. ³Université de Montpellier, Montpellier 34090, France. ⁴IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier 34298, France. ⁵Inserm, U1194, Montpellier 34298, France. ⁶ICM, Institut régional du Cancer de Montpellier, Montpellier 34298, France. ⁷Inserm U1040, Montpellier 34295, France. ⁸Inserm U661, Montpellier 34094, France. ⁹CNRS UMR5203, Institut de Génomique Fonctionnelle, Montpellier 34094, France. ¹⁰NovAliX, Illkirch 67400, France. ¹¹INRA UMR 1331, TOXALIM, Sophia-Antipolis 06903, France. ¹²CHU de Montpellier, Institut de Recherche en Biothérapie, Montpellier 34295, France. * These authors equally contributed to this work. ** These authors jointly supervised this work. Correspondence and requests for materials should be addressed to P.B. (email: patrick.balaguer@inserm.fr) or to W.B. (email: bourguet@cbs.cnrs.fr).
External compounds (xenobiotics) to which humans are continuously exposed include environmental pollutants, drugs or dietary components. Many of them belong to the structurally heterogeneous group of endocrine-disrupting chemicals (EDCs) that trigger adverse health effects by mimicking or antagonizing the action of endogenous signalling molecules. More than 20 years of experimental and epidemiological studies have highlighted the pivotal role of nuclear receptors (NRs) in transducing many of the harmful effects of EDCs. NRs belong to a large family of evolutionarily related transcription factors that control complex gene networks, resulting in profound physiological changes. They contain a ligand-binding domain (LBD) that responds to a wide variety of endogenous hormonal and metabolic ligands. The endocrine-disrupting action of chemicals relies mostly on their ability to substitute for natural ligands and deregulate NR signalling, causing reproductive, proliferative and metabolic disorders. In addition, human exposure to mixtures of xenobiotics can induce unpredictable additive, antagonistic or synergistic adverse effects. Yet, the molecular mechanisms underlying these cocktail effects are largely unknown.

To explore the outcome of combined exposure to chemicals and establish a detailed mechanistic understanding of this emerging paradigm for EDC action, we focused our attention on the xenoreceptor PXR (pregnane X receptor; NR1I2) which has been identified by the US Environmental Protection Agency ToxCast’s program as a major front-line target of chemicals. This NR is a key regulator of the body’s defense against foreign substances. It forms heterodimers with the retinoid X receptor (RXR) and binds to PXR responsive elements (PXRE) in the regulatory regions of target genes. Upon activation by xenobiotics (for example, bisphenol-A, organophosphate pesticides, alkylphenols, rifampicin), PXR interacts with coactivators, such as the steroid receptor coactivator-1 (SRC-1), and transcriptionally upregulates major detoxification genes such as the phase I cytochrome P450 enzyme CYP3A4 (ref. 11), which metabolizes more than half of all drugs in clinical use. On the other hand, the interaction of PXR with EDCs has been linked to an increased risk of cardiovascular and metabolic diseases.

Here, using compound screening followed by extensive functional analysis, we demonstrate that the combined use of the pesticide trans-nonachlor (TNC) and the active component of contraceptive pills, 17α-ethinylestradiol (EE2), produces synergistic effects on PXR activation and expression of its endogenous target gene CYP3A4. Biophysical characterization reveals that EE2 and TNC bind cooperatively to PXR and that the binary mixture has considerably improved functional properties over each of the compounds alone. Crystallographic analysis shows that reciprocal stabilization of the compounds in the ligand-binding pocket (LBP) of the receptor accounts for the enhanced efficacy and potency of the chemical mixture. We therefore propose the concept of a ‘supramolecular ligand’ that defines a molecular assembly consisting of two or more compounds that interact with each other inside the LBP of a receptor, resulting in the creation of a new entity with improved functional characteristics in regard to those of its individual components.

**Cocktail effect on CYP3A4 expression and activity.** Consistent with the reporter gene assays, the effectiveness of the individual compounds at increasing the level of endogenous CYP3A4 mRNA was drastically enhanced by the addition of the second compound in LS174T cells expressing PXR but not in control cells (Fig. 2d). We then compared the ability of EE2 and TNC, alone or in combination, to increase CYP3A4 gene expression in freshly isolated primary human hepatocytes (PHHs) in culture, the most biologically relevant model regarding PXR function. As shown in Fig. 2e, the CYP3A4 mRNA expression was considerably augmented when both EE2 and TNC were used. Accordingly, the enhanced induction of the CYP3A4 protein by the binary mixture (Fig. 2f, upper panel and Supplementary Fig. 3) closely correlated with higher CYP3A4 enzymatic activity (Fig. 2f, lower panel).

As a whole, cell-based assays clearly show that EE2 and TNC act as poor PXR agonists when used separately whereas their combination triggers PXR activation nearly as efficiently as the reference agonist SR12813. Notably, synergism could be observed in various cellular contexts and with different compound combinations, including the natural hormone 17β-estradiol.

**Results**

**Synergistic activation of PXR by EE2 and TNC.** Using medium throughput ligand screening and a mammalian (HeLa) cell-based activation assay (HG5LN GAL4-PXR-LBD reporter cell line), we monitored the agonistic potential of 40 chemicals either alone or in binary mixtures (Supplementary Table 1). Most combinations exhibited additive effects, inducing 50–60% of the transactivation seen with the cholesterol-lowering drug SR12813 (Fig. 1), a potent and well-characterized PXR full agonist (EC50 in the 100–200 nM range) used as a reference in all our experiments. However, we observed that the combined use of the organochlorine pesticide TNC and the synthetic oestrogen 17α-ethinylestradiol (EE2), the active component of contraceptive pills, produced more than an additive effect with an induction level of 90% (Fig. 1 and Supplementary Fig. 1). This preliminary observation was confirmed by dose–response experiments. The combination of TNC and EE2 led to a shift of the corresponding activation curve by one order of magnitude towards the low concentrations (Fig. 2a). We next examined the effect of TNC, EE2, and their combination in human liver (HepG2) and colon (LS174T) carcinoma cell lines containing the full-length PXR and the CYP3A4-XREM luciferase reporter plasmids. Again, we found that co-treatment yielded to much stronger activation of PXR as monitored by the transactivation of the CYP3A4 reporter gene (Fig. 2b,c). When used simultaneously, the two compounds activated PXR in a synergistic fashion as illustrated by the theoretical activation curve obtained for the additive combination of EE2 and TNC activities (Fig. 2a–c, red dashed lines calculated using the Bliss independence model). Note that synergism was also observed with other steroid and organochlorine compound combinations. Supplementary Fig. 2 shows two representative examples associating either EE2 and cis-chlordane, or TNC with the natural hormone 17β-estradiol (Fig. 1).

**Figure 1** | Chemical structures of compounds used in this study.
Coactivator recruitment by PXR upon co-treatment. In order to decipher the molecular mechanism involved in the synergistic activation of PXR-mediated transcription by EE2 and TNC, we characterized their impact on coactivator recruitment. For this purpose, we used fluorescence anisotropy assays with the purified PXR/RXR LBD heterodimers and the fluorescein-labelled NR interaction domain (NID) of SRC-1. We found that, as expected, the PXR agonist SR12813 efficiently enhanced SRC-1 recruitment (Fig. 3a). Interestingly, EE2 and TNC had modest effects on their own but their combination produced a strong increase in the coactivator recruitment, similar to that observed with SR12813. Comparable results were obtained from mammalian two-hybrid experiments (Fig. 3b), suggesting that the active form of the receptor is highly stabilized in presence of both ligands.
Simultaneous binding of EE2 and TNC to PXR. To characterize further the interaction of PXR with EE2 and TNC, we used electrospray ionization mass spectrometry (ESI-MS) under native conditions. Analysed separately, TNC and EE2 were shown to interact with PXR with affinities in the low micromolar range; about 80 and 70% complex were detected when PXR (10 μM) was incubated with 2 molar equivalent excess of TNC or EE2, respectively (Fig. 4a-c). TNC bound to PXR in a 1:1 molar ratio, while EE2 was found to interact with the receptor with 1:1 and 1:2 binding stoichiometries. Binding specificity of the two compounds for PXR ligand-binding pocket was assessed using competition experiments against SR12813. As shown in Supplementary Fig. 4, SR12813 was able to compete efficiently for EE2 and TNC. No non-specific binding was detected with TNC, whereas some residual EE2 was observed in presence of SR12813, suggesting that part of the secondary EE2 binding sites could reside outside the PXR LBP. Analysis of PXR after incubation with the binary cocktail showed a large predominance of a ternary complex corresponding to PXR binding sites could reside outside the PXR LBP. Analysis of PXR after incubation with the binary cocktail showed a large predominance of a ternary complex corresponding to PXR

EE2 and TNC bind cooperatively to PXR. We next assessed the binding characteristics of EE2 and TNC, alone or in mixture, to PXR. Competitive binding assays using time resolved fluorescence resonance energy transfer between a fluorescent PXR ligand and purified human PXR-LBD (LanthaScreen TR-FRET PXR Competitive Binding Assay) showed that the binary mixture binds 10- to 30-fold more avidly to PXR than TNC and EE2 alone (Fig. 5a). To define the receptor–ligand interactions by a direct method, we next measured the binding affinity constants of various EE2 and TNC combinations by isothermal titration calorimetry (ITC). Before ITC experiments, dose-dependent aggregation of the compounds in working buffer was assessed using dynamic light scattering. Critical aggregation concentration (CAC) was estimated to be in the 50-100 μM range when compounds were diluted serially from 500 μM down to 3 μM in Tris-HCl 20 mM, pH 8.5, NaCl 200 mM, TCEP 1 mM, Tween20 0.05%, DMSO 5%. Accordingly, we cannot rule out that when used at 200-300 μM in some experimental conditions, a fraction of the compounds undergo aggregation despite the dilution process occurring during titration experiments (see Methods). Nevertheless, ITC analyses clearly converged towards similar conclusion of cooperative binding of EE2 and TNC to PXR resulting in increased global binding affinity. ITC data showed much better affinities of EE2 and TNC for PXR when the receptor was pre-incubated with TNC or EE2, respectively (Kd values in

Figure 4 | Simultaneous binding of EE2 and TNC to PXR. Mass spectrometry analysis. Non-denaturing ESI-MS was used to characterize PXR LBD (10 μM) in (a) the unliganded form or in the presence of (b) EE2 (20 μM), (c) TNC (20 μM), or (d) a mixture of EE2 (20 μM) and TNC (20 μM). *, acetate adducts; $, fortuitous binders 254-324 Da; #, fortuitous binder 254 Da; #, non-specific EE2 adducts.

Figure 5 | EE2 and TNC bind cooperatively to PXR. (a) Inhibition of FRET between fluorescein-labelled PXR ligand and recombinant GST-PXR by SR12813, TNC and EE2, alone or in combination. Results are expressed as the signal from the fluorescein emission divided by the terbium signal to provide a TR-FRET emission ratio. Data are the mean (± s.e.m.) from three separate experiments. (b-f) Isothermal titration calorimetry (ITC) characterization of PXR interaction with EE2 and TNC. Ligands were titrated either independently (b,c), after pre-incubating the receptor with EE2 (d) or TNC (e), or simultaneously (f). In b-f, representative thermograms (upper row) and corresponding binding isotherms (lower row) are shown. Kd values are expressed as the mean of two independent experiments.
\textbf{NATURE COMMUNICATIONS | DOI: 10.1038/ncomms9089}

\section*{Results}

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure1.png}
\caption{\textbf{a} 520 nm/495 nm ratio at different ligand concentrations. \textbf{b} Molar ratio and \(K_d\) for PXR/EE2. \textbf{c} Molar ratio and \(K_d\) for PXR/TNC. \textbf{d} Molar ratio and \(K_d\) for PXR+TNC/EE2. \textbf{e} Molar ratio and \(K_d\) for PXR+EE2/TNC. \textbf{f} Molar ratio and \(K_d\) for PXR/EE2+TNC.}
\end{figure}

\begin{table}[h]
\centering
\begin{tabular}{|c|c|}
\hline
Ligand & \(K_d\) (nM) \\
\hline
EE2 & 11.50 ± 5.42 \\
TNC & 3.01 ± 1.07 \\
TNC+EE2 & 0.33 ± 0.07 \\
SR12813 & 0.11 ± 0.02 \\
\hline
\end{tabular}
\caption{Binding constants for different ligands.}
\end{table}

\begin{table}[h]
\centering
\begin{tabular}{|c|c|c|}
\hline
[Ligand] (M) & \(K_i\) (μM) \\
\hline
10–9 & 11.50 ± 5.42 \\
10–8 & 3.01 ± 1.07 \\
10–7 & 0.33 ± 0.07 \\
10–6 & 0.11 ± 0.02 \\
10–5 & 0.16 \\
10–4 & 5.20 nm/495 nm ratio \\
\hline
\end{tabular}
\caption{Inhibition constants for different ligands.}
\end{table}

\begin{table}[h]
\centering
\begin{tabular}{|c|c|}
\hline
[Ligand] (M) & \(K_d\) (μM) \\
\hline
10–9 & 11.50 ± 5.42 \\
10–8 & 3.01 ± 1.07 \\
10–7 & 0.33 ± 0.07 \\
10–6 & 0.11 ± 0.02 \\
10–5 & 0.16 \\
10–4 & 5.20 nm/495 nm ratio \\
\hline
\end{tabular}
\caption{Inhibition constants for different ligands.}
\end{table}
the high-nanomolar range compared to the mid-micromolar range interaction of the compounds tested independently; Fig. 5b-e). Simultaneous titration of EE2 and TNC against PXR was associated with a binding affinity of the binary mixture that was substantially higher than those of the compounds tested alone (Fig. 5f), corroborating the observations derived from ESI-MS and LanthaScreen experiments.

Taken altogether, these in vitro data performed with purified material strongly support the notion that both the cooperative binding and synergism observed with EE2 and TNC rely on direct interactions with PXR and not on other cellular mechanisms such as cellular influx/efflux, metabolism, or binding to other cellular targets.

### Table 1 | Data collection and refinement statistics.

| Data collection | EE2 (4X1F) | TNC (4XAO) | EE2 + TNC (4X1G) |
|-----------------|------------|------------|------------------|
| Space group     | $P4_1 2_1 2$ | $P4_1 2_1 2$ | $P4_1 2_1 2$ |
| Cell dimensions | 91.34, 91.34, 85.35 | 92.30, 92.40, 86.30 | 91.34, 91.34, 85.49 |
| $a, b, c$ (Å)   | 90.00, 90.00, 90.00 | 90.00, 90.00, 90.00 | 90.00, 90.00, 90.00 |
| Resolution (Å)  | 45.67–2.00 (2.11–2.00)* | 41.28–2.58 (2.69–2.58)* | 40.85–2.25 (2.38–2.25)* |
| $R_{	ext{sym}}$ | 0.080 (0.489) | 0.110 (0.472) | 0.091 (0.453) |
| Completeness (%) | 100.0 (100.0) | 96.8 (78.3) | 97.7 (99.0) |
| Redundancy      | 10.4 (10.4) | 7.8 (7.3) | 5.4 (5.2) |

| Refinement      | EE2 (4X1F) | TNC (4XAO) | EE2 + TNC (4X1G) |
|-----------------|------------|------------|------------------|
| Resolution (Å)  | 45.67–2.00 | 41.28–2.58 | 38.71–2.25 |
| No. reflections | 24,998     | 12,258     | 17,316           |
| $R_{	ext{work}}$/$R_{	ext{free}}$ | 0.182/0.209 | 0.189/0.239 | 0.174/0.218 |
| No. atoms       | Protein 2,158 | 2,171     | 2,208            |
|                 | Ligand/ion 38 | 12        | 53               |
|                 | Water 170     | 67        | 122              |
| $B$-factors     | Protein 30.19             | 39.48     | 34.80            |
|                 | Ligand/ion 40.29           | 57.14     | 48.99            |
|                 | Water 37.31               | 40.64     | 39.36            |
| R.m.s.deviations | Bond lengths (Å) 0.009     | 0.002     | 0.008            |
|                 | Bond angles (°) 0.996      | 0.569     | 1.067            |

R.m.s, root-mean square; TNC, trans-nonachlor. *Values in parentheses are for highest-resolution shell.

Structural basis for supramolecular ligand activity. To gain structure-based insight into the binding mode of EE2 and TNC to PXR, we solved the crystal structures of PXR-LBD in complex with EE2, TNC, or both at 2.00 Å, 2.55 Å, and 2.25 Å resolution, respectively (Table 1 and Supplementary Fig. 5). In all cases, the PXR-LBD adopts the canonical active conformation, with the C-terminal activation helix H12 capping the LBP (Fig. 6a and Supplementary Fig. 6a,b). Whereas EE2 could be precisely placed in the electron densities obtained for both the PXR–EE2 and PXR–TNC–EE2 complexes, TNC could be positioned unambiguously in the ternary complex only (Fig. 6b and Supplementary Fig. 6a,b). The poorly defined electron density leaves a significant portion of the pocket unoccupied and available for additional interactions (Supplementary Fig. 6a,c). The remaining contacts between EE2 and the protein involve van der Waals interactions with several hydrophobic residues. The particular position of EE2 in a restricted region of PXR LBP leaves a significant portion of the pocket unoccupied and available for additional interactions (Supplementary Fig. 6a,c). As seen in the ternary complex, this empty region can accommodate one molecule of TNC which is stabilized in a well-defined position via a number of interactions with both EE2 and the protein. As illustrated in Fig. 6c, eight van der Waals contacts of 3.7 to 4.5 Å in length could be measured between EE2 and TNC. These inter-ligand contacts generate a mutual stabilization of the compounds in the LBP and account for the enhanced binding affinity of the binary mixture (Fig. 5). On the protein side, TNC forms essentially nonpolar interactions with ten residues, including F281, F288, W299, Y306, M323 (Fig. 6c) and two weak halogen bonds with Q285 and C284 from helix H5.

In keeping with the robust agonistic activity of the binary mixture, superposition of the supramolecular ligand-bound structure with that of PXR in complex with SR12813 (ref. 21) or rifampicin22 reveals that the binding sites of EE2 and TNC overlap those of the two PXR agonists (Supplementary Fig. 7b,c). Hence, the molecular assembly of EE2 and TNC into the LBP of PXR can be regarded as a supramolecular ligand whose functional properties rely on intermolecular interactions and differ from those of the individual components.

### Discussion

Most current knowledge of EDCs action is derived from data sets that use single molecule exposure, with few studies taking into account the more realistic situation where humans are...
simultaneously and chronically exposed to low doses of multiple EDCs. Indeed, a growing number of studies indicate that human risk assessment approaches based on single molecule exposure underestimate the risk for adverse effects of chemicals\(^\text{19}\). The evaluation of mixture effects by regulatory bodies has been mainly hampered by the huge numbers of pollutants and potential combinations, but also by the lack of knowledge of the molecular pathways involved. This study provides both the first detailed mechanistic explanation and a proof of concept for the synergistic action of two compounds via their simultaneous interaction with the LBP of a NR. Our results provide not only new insight as to how low doses of EDCs or drugs may affect physiology and homeostasis, but also suggest that the concomitant binding of chemicals stabilizing each other in NR LBPs likely corresponds to one of the possible mechanisms accounting for the cocktail effect by which compounds toxicity is exacerbated.

Reports describing the simultaneous binding of two or more compounds to a common protein binding site are very few in number. One of the rare examples is that of the *Staphylococcus aureus* multidrug-binding transcription repressor QacR which was shown to bind concomitantly to ethidium and proflavin. However no cooperative binding mechanism was observed in this case\(^\text{23}\). Other examples include the cytochrome CYP3A4 bound to two molecules of ketoconazole\(^\text{24}\) or the peroxisome proliferator activated receptor gamma (PPAR\(\gamma\)) which can accommodate two copies of FMOC-L-Leucine\(^\text{25}\), or endogenous fatty acids\(^\text{26}\). However, in both cases the bound molecules were of the same type and the possibility of synergism between the two ligands was not addressed. Besides the interaction of several compounds with a unique binding site, two studies reported on the oestrogen antagonist 4-hydroxytamoxifen and a synthetic ligand binding to two alternate sites of the oestrogen receptor \(\beta\) and PPAR\(\gamma\) LBDS, respectively\(^\text{27,28}\). Again, no cooperativity was reported between these dual binding sites. Our study shows that individually, EE2 and TNC are too small to make all the necessary interactions ensuring high binding affinity and effective stabilization of the active conformation of the receptor. In contrast, when associated in a binary mixture, EE2 and TNC form a supramolecular ligand that fills a larger fraction of the PXR LBP, and displays apparent functional properties (e.g. activity and binding affinity) comparable to those of the full PXR agonists, SR12813 and rifampicin.

Cloning of PXR orthologues from human, rabbit, rat and mouse has shown that the ligand-binding domain has diverged considerably between the different species, leading to specific ligand-binding and activation profiles\(^\text{29,30}\). This species-specific induction pattern of PXR is possibly an adaptive response to the environment and a need to adjust toxicological responses to endogenously produced substances. Therefore, additional studies should be performed to test the potential EE2/TNC synergy *in vivo* in these species. Notably future studies will be completed in mice, along with the use of PXR-knock-out models and long term exposures with these compounds, to confirm the role of PXR and the physiological relevance of the EE2/TNC synergism on drug and bile acid metabolism, hepatic steatosis, or liver regeneration for instance.

Large LBPs such as those of PXR or PPAR\(\gamma\) are obviously predisposed to accommodate several molecules at the same time. However, in contrast to the perception that most NRs possess a well-defined pocket to account for the specific binding of a unique endogenous ligand, several structural studies have revealed that their LBPs exhibit a greater conformational flexibility than previously thought. Importantly, this structural adaptability allows the oestrogen (ER\(\alpha\))\(^\text{31}\), thyroid (TR\(\beta\))\(^\text{32}\), or glucocorticoid (GR)\(^\text{33}\) receptors to expand their binding pocket and accommodate much larger ligands\(^\text{34}\). Another interesting example is the oestrogen-related receptor gamma (ERR\(\gamma\)) whose LBP appears too small to bind any ligand, yet can expand it to accommodate rather large compounds\(^\text{35}\). Considering the huge chemical and size diversity of xenobiotics and the high structural plasticity of NR LBPs, the mechanism defined for PXR is likely to occur also with other members of the NR superfamily, with broad reaching implications in the fields of endocrine disruption, chemicals risk assessment and toxicology. The development of novel supramolecular chemistry-based therapeutic options could also benefit from the discovery reported here.

**Methods**

**Ligands.** TNC, EE2, E2 and CC were purchased from Sigma-Aldrich. SR12813 was purchased from Tocris Bioscience. The provenance of compounds used for medium-throughput screening is described in Supplementary Table 1. All compound stock solutions were prepared at 10 mM in DMSO.
Plasmids. The [−7.8/−2] XRE-M-CYP3A4 (XRE-M-CYP3A4 pGL3b) luciferase plasmid has been described previously39. The 17Mx5-Glob-LUC containing five GAL4 binding sites upstream of the luciferase reporter gene and the VP16 (activation domain)-TIF2 (amino acids 624-869 containing three LXXLL motifs) are gifts from Hinrich Gronemer (IGBMC, Illkirch, France). The m-P-hPXR expression vector was generated by inserting a PCR fragment corresponding to the full-length hPXR in the pM vector (CLONTECH).

Cell lines. LS174T stable human PXR transfectant (LS-PXR2) and the corresponding control cells (LS-CTRL), HEPG2-PXR and HG5LN GAL4-PXR reporter cell lines were previously described17,37,38. Briefly, LS-PXR2 was obtained after stable transfection of the LS174T cells with the pCDNA3.1-hPXR (residues 1-434)-neomycin expressing plasmid. HEPG2-PXR was obtained after stable transfection of the same PXR expressing plasmid and the XREM-CYP3A4 pGL3b reporter plasmid37. HEPG2-PXR reporter cell line was established by stable transfection of pG5-GAL4DBD (residues 107-143)-puromycin and GAL4-RE5-Glucoluciferase-neomycin plasmids17. Finally, LS174T-PXR reporter cell line was established by stable transfection of the CYP3A4-luciferase-hygromycine plasmid in the LS-PXR2 cell line. All cell lines were grown in DMEM medium (Invitrogen) supplemented with 10% fetal calf serum, L-glutamine, and antibiotics (Invitrogen).

Medium-throughput screening. HGSLn GAL4-PXR reporter cell lines (100 μl) were seeded at a density of 25,000 cells per well in 96-well white opaque tissue culture plates (Greiner CellStar). 24 h later, negative (DMSO 0.1%) and positive (propyl-β-D-thiogalactoside to a final concentration of 0.5 mM) controls, and the 40 tested compounds (50 μM) were added into the wells as indicated in Supplementary Table 1. Then the ligand to be tested in combination with the ligand was added to each well. Cells were incubated at 37 °C for 16 h. At the end of the incubation period, culture medium was replaced with medium containing 3.10−4 M luciferin. Luciferase activity was measured for 2 s in intact living cells using a plate reader (PerkinElmer Luminometer).

Transactivation assays. HGS LN GAL4-PXR, HEPG2- and LS174T-PXR reporter cell lines were seeded at a density of 25,000 cells per well in 96-well white opaque tissue culture plates (Greiner CellStar). Compounds to be tested were added 24 h later, and cells were incubated at 37 °C for 16 h. At the end of the incubation period, culture medium was replaced with medium containing 3.10−4 M luciferin. Luciferase activity was measured for 2 s in intact living cells using a plate reader (PerkinElmer Luminometer). EC50 values were measured using GraphPad Prism (GraphPad Software Inc.).

Preparation of primary human hepatocytes. Liver samples were obtained from liver resections performed in adult patients for medical reasons unrelated to our research program or from donors when the liver was considered unsuitable for organ transplantation. The use of human specimens for scientific purposes was approved by the French National Ethics Committee. Written or oral informed consent was obtained from each patient or family prior to surgery. The clinical characteristics of the liver donors are presented in Supplementary Table 2. Hepatocytes were isolated by using a two-step perfusion protocol and cultured as described previously39. Briefly, several veins apparent on the cut edge of the lobectomy were used for sequential perfusions with a washing buffer (10 mM HEPES, 136 mM NaCl, 5 mM KCl, 0.5% glucose, pH 7.6), with a calcium chelating buffer (washing buffer complemented with 0.5 mM EGTA), with the washing buffer (washing buffer complemented with 0.5 mM EGTA and 0.5% (v/v) glycerol). The fluorescein-labelled SRC-1 fragment (residues 570−780) was prepared using the protocol previously described40. Briefly, the SRC-1 fragment was expressed in E. coli BL21(DE3) as a fusion with an inducible self-splicing intein (Sce VMA) and a chitin-binding domain using the vector pTYB1 (New England Biolabs). The cells were grown at 37 °C to OD600 0.6 at OD600 and then at 17 °C overnight. The fusion protein was purified using chitin resin (New England Biolabs). Inein cleavage was induced using 2 μM cys-fluor with 50 μM MESSNA, releasing C-terminally labelled SRC-1. Excess cys-fluor was removed using a phenyl sepharose resin (Amersham). SRC-1 was further purified using size-exclusion chromatography. Thin-layer chromato-graphy was used to confirm that there was no free fluorescein label in the purified samples.

Steady-state fluorescence anisotropy assay. Measurement of the binding affinities of the coactivator fragment for the PXR/RXR heterodimer in the absence and presence of various ligands was performed using a Safire2 microplate reader (TECAN). The excitation wavelength was set at 470 nm and emission measured at 530 nm for the fluorescence-tagged fragment. Assays were carried out in the following buffer solution 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM TCEP and 5% (v/v) glycerol. We initiated the measurements at the highest concentration of protein (20 μM) and diluted the protein sample twofold successively with the buffer solution. For each point of the titration curve, the protein sample was mixed with 5 mM of fluorescence fragment and a 3 molar excess of ligand (60 μM final concentrations). Binding data were fitted using a sigmoidal dose–response model using GraphPad Prism (GraphPad Software Inc.).

Mammalian two-hybrid experiments. Gal4-hPXR and VP16-TIF2 interaction was monitored on 17Mx5-Glob-LUC reporter construct. Transient transfections assays were performed in U2OS cells using Jet-PEI (Ozyme) according to the manufacturer’s instructions. Luciferase assays were performed with the Promega dual-reporter kit, according to the manufacture’s instructions. Renilla luciferase encoded by the normalization vector pHRLTK (Promega) was used as internal control for firefly luciferase normalization.

Measurement of CYP3A4 activity. Primary human hepatocytes were seeded in 96-well plates and treated with compounds of interest. CYP3A4 activity was detected using the P450 Glo CYP3A4 Luciferin-IPPA Enzyme Activity Kit (Promega) according to the manufacturer’s instructions. Cell number was normalized using CellTiter-Glo Luminescent Cell Viability Assay (Promega).

Statistical analyses. For the analysis of the correlation between parametric data, Student’s t-test was used, while the Mann–Whitney U-test was used for nonparametric data. Differences were considered statistically significant when P-values were ***P<0.001 **P<0.01 *P<0.05.
Mass spectrometry. Mass spectrometry experiments were carried out on an electrospray time-of-flight mass spectrometer (LCT, Waters) equipped with an atmospheric pressure ionization-based nanospray device (Thermo Nanomate, Advion Biosciences). External calibration was done in the positive ion mode over the mass range m/z 500–5,000 using the multiply charged ions produced by 0.5 mM horse heart myoglobin solution diluted in water/acetonitrile 50:50 mixture acidified with 0.5% (v/v) formic acid. Purified PXR(130-434)-SRC1 was buffer exchanged against 0.5 M ammonium acetate, pH 8.0 using NAP5 desalting columns (illustra NAP-5 Columns, GE Healthcare Life Sciences). Protein concentration was determined spectrophotometrically (ε280nm = 26,210 M⁻¹ cm⁻¹). Analysis of EE2 and TNC binding to PXR(130-434)-SRC1 was achieved in 50 mM NH4Ac pH 8.0, keeping a constant amount of incoming ligand (mM). Protein concentration was set to 10 μM and different compound concentrations ranging from 20 to 80 μM were tested. Incubations lasted 5 min at 18°C. Mass spectra were recorded using low cone voltage (Ve, 20 V) and elevated interface pressure (Pi, 5 mbar).

Lanthascreen TR-FRET PXR competitive binding assay. GST-hPXR-LBD (10 mM) was incubated with different concentrations (10−30 μM) of TNC, EE2, TNC and EE2, and SR12813 in the presence of fluorescein PXR ligand (40 mM) and Lanthascreen terbium-anti-GST antibody (10 nM). To read a Lanthascreen TR-FRET assay, the fluorometer (PhereaStar FS; MBG LABTECH) is configured to excite the terbium donor around 340 nm, and to separately read the terbium emission peak that is centred at ~490 nm, and the fluorescein emission that is centred at ~520 nm. Results are expressed as the signal from the fluorescein emission divided by the terbium signal to provide a TR-FRET emission ratio. Fluorescence ratio data were fitted using a sigmoidal dose–response model using GraphPad Prism (GraphPad Software Inc.).

Isothermal titration calorimetry. Purified PXR(130-434)-SRC1 was dialysed overnight against Tris-HCl 20 mM, pH 8.5, NaCl 200 mM, TCEP 1 mM supplemented with 0.05% (v/v) Triton X-100 and then subjected to sonication. The clarified cell lysate was applied onto a Ni2⁺-charged resin containing 20 mM Tris pH 7.8, 250 mM NaCl, 5% (v/v) glycerol, 5 mM DTT, 1 mM PMSF, 50 μg/ml RNase A, 1 mg/ml aprotinin. The clarified lysate was applied onto affinity chromatography (ILynx 50; GE Healthcare) equilibrated with a buffer containing 20 mM Tris pH 7.8, 250 mM NaCl, 5% (v/v) glycerol, 5 mM DTT, 1 mM EDTA. The PXR-LBD was concentrated and stored at −40°C.

Crystallization. Prior to crystallization assays the purified PXR-LBD (2.4 mg/ml) was mixed with 12% (w/v) PEG 400, 100 mM NaCl, 10% (v/v) glycerol, and then subjected to centrifugation at 20,000g for 10 min. The clarified packed solution was equilibrated at 20°C against the reservoir solution.

Data collection and structure determination. For all complexes, native data were collected from one crystal microcontacted with 20% (v/v) MPD on the ID23-2 beamline at the European Synchrotron Radiation Facilities (λ = 0.8726 Å, 100 K, Grenoble, France). Data were processed and scaled with XDS and XSCALXE5. Crystals belong to space group P 4₁ 2₁ 2. The X-ray structures were solved and refined at 1.64 Å resolution using Phenix refine5. The percentage of residues located in the favoured Ramachandran plot region are 98.1, 98.2 and 97.9% for the PXR – EE2, PXR – TNC and PXR – EE2 unliganded crystal structures, respectively (calculated with MolProbity48). Data collection and refinement statistics are summarized in Table 1. Figures were prepared with PyMOL (http://pymol.org/).

References

1. Diamanti-Kandarakis, E. et al. Endocrine-disrupting chemicals: an Endocrine Society scientific statement. Endocr. Rev. 30, 293–342 (2009).
2. De Coster, S. & van Larebeke, N. Endocrine-disrupting chemicals: associated disorders and mechanisms of action. J. Environ. Public Health 2012, 713696 (2012).
3. Schug, T. T., Janesick, A., Blumberg, B. & Heindel, J. J. Endocrine disrupting chemicals and disease susceptibility. J. Steroid Biochem. Mol. Biol. 127, 204–215 (2011).
4. Janosek, J., Hilscherova, K., Blaha, L. & Holubek, I. Environmental xenobiotics and nuclear receptors–interactions, effects and in vitro assessment. Toxicol. In Vitro 20, 18–37 (2006).
5. Swedenborg, E., Ruegg, J., Makela, S. & Pongratz, I. Endocrine disruptive chemicals: mechanisms of action and involvement in metabolic disorders. J. Endocrinol. Invest. 34, 1–10 (2009).
6. Germain, P., Staels, B., Daucuet, C., Spedding, M. & Laudet, V. Overview of nomenclature of nuclear receptors. Pharmacol. Rev. 58, 685–704 (2006).
7. Grun, F. & Blumberg, B. Perturbed nuclear receptor signaling by environmental obesogens as emerging factors in the obesity crisis. Rev. Endocr. Metab. Disord. 11, 189–197 (2010).
8. Newbold, R. R., Jefferson, W. N. & Padilla-Banks, E. Prenatal exposure to bisphenol a at environmentally relevant doses adversely affects the murine female reproductive tract later in life. Environ. Health Perspect. 117, 879–885 (2009).
9. Rubin, B. S. & Soto, A. M. Bisphenol A: perinatal exposure and body weight. Mol. Cell. Endocrinol. 304, 1–10 (2009).
10. Kortenkamp, A. Low dose mixture effects of endocrine disrupters and their implications for regulatory thresholds in chemical risk assessment. Crit. Opin. Pharmacol. 19C, 105–111 (2014).
11. Lehmann, J. M. et al. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Invest. 102, 1016–1023 (1998).
12. Sui, Y. et al. Bisphenol A increases atherosclerosis in pregnant X receptor-humanized ApoE deficient mice. J. Am. Heart Assoc. 3, e000492 (2014).
13. Chaturvedi, N. K., Kumar, S., Negi, S. & Tyagi, R. K. Endocrine disruptors provoke differential modulatory responses on androgen receptor and pregnane and xenobiotic receptor: potential implications in metabolic disorders. Mol. Cell. Biochem. 345, 291–308 (2010).
14. Lemaire, G. et al. Identification of new human pregnane X receptor ligands among pesticides using a stable reporter cell system. Toxicol. Sci. 91, 501–509 (2006).
15. Mnif, W. et al. Estrogens and antioxidants activate hPXR. Toxicol. Lett. 170, 189–199 (2007).
16. Jones, S. A. et al. The pregnant X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Mol. Endocrinol. 14, 27–39 (2000).
17. Lemaire, G. et al. Discovery of a highly active ligand of human pregnane x receptor: a case study from pharmacophore modeling and virtual screening to ‘in vivo’ biological activity. Mol. Pharmacol. 72, 572–581 (2007).
18. Watkins, R. E. et al. The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science 292, 2329–2333 (2001).
19. Zhao, W. et al. A new bliss independence model to analyze drug combination data. J. Biomol. Screen. 19, 817–821 (2014).
20. Xue, Y. et al. Crystal structure of the pregnant X receptor–estradiol complex provides insights into endobiotic recognition. Mol. Endocrinol. 21, 1028–1038 (2007).
21. Watkins, R. E., Davis-Searles, P. R., Lambert, M. H. & Redinbo, M. R. Coactivator binding promotes the specific interaction between ligand and the pregnant X receptor. J. Biol. Chem. 331, 815–828 (2003).
22. Chrenchik, J. E. et al. Structural disorder in the complex of human pregnane x receptor and the macrodide antibiotic rifampicin. Mol. Endocrinol. 19, 1125–1134 (2005).
23. Schumacher, M. A., Miller, M. C. & Brennan, R. G. Structural mechanism of the simultaneous binding of two drugs to a multidrug-binding protein. EMBO J. 23, 2923–2930 (2004).
24. Ekroos, M. & Sjogren, T. Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc. Natl Acad. Sci. USA 103, 13682–13687 (2006).
25. Rocchi, S. et al. A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol. Cell. 8, 737–747 (2001).
26. Itoh, T. et al. Structural basis for the activation of PPARgamma by oxidized fatty acids. Nat. Struct. Mol. Biol. 15, 924–931 (2008).
27. Wang, Y. et al. A second binding site for hydroxytamoxifen within the coactivator-binding groove of estrogen receptor beta. Proc. Natl Acad. Sci. USA 103, 9008–9011 (2006).
28. Hughes, T. S. et al. An alternate binding site for PPARgamma ligands. Nat. Commun. 5, 3571 (2014).
Acknowledgements

We thank Matthew Redinbo for providing the expression plasmid used for crystallographic studies. We acknowledge the experimental assistance from the staff of the European Synchrotron Radiation Facility (ESRF, Grenoble, France) during data collection. We thank Diego Tosi for calculation of the theoretical additive activity curves and Catherine Teysier for preparation of fluorescence-labeled SRC-1 NID. We acknowledge the financial support from the Agence Nationale de la Recherche, project TOXSYN ANR-13-CESA-0017-03 (P.B. and W.B.), and Plan Cancer Inserm, project SYNERPXR A12156FS (J.M.P., P.B. and W.B.).

Author contributions

J.M.P., P.B. and W.B. conceived the project. V.D. and T.H. performed the crystallographic and fluorescence anisotropy studies. B.D., M.G., A.B., B.B. and P.B. performed screening and cell-based assays. S.G.C., M.D.C. and J.M.P performed CYP3A4 analysis. V.C. analysed data. R.R. provided biological tools. D.R., C.M. and V.V. performed mass spectrometry and ITC measurements. J.M.P., P.B. and W.B. wrote the manuscript. All authors contributed to editing of the manuscript.

Additional information

Accession codes: The atomic coordinates and structure factors have been deposited in the Protein Data Bank under accession codes 4X1F (EE2), 4XAO (TNC) and 4X1G (EE2 + TNC).

Supplementary Information accompanies this paper at http://www.nature.com/naturecommunications

Competing financial interests: The authors declare no competing financial interests.

Reprints and permission information is available online at http://npg.nature.com/reprintsandpermissions/

How to cite this article: Delissone, V. et al. Synergistic activation of human pregnane X receptor by binary cocktails of pharmaceutical and environmental compounds. Nat. Commun. 6:8089 doi: 10.1038/ncomms9089 (2015).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/